What does Cigna’s prior authorization policy for Eylea (aflibercept) require for coverage?
Cigna’s commercial prior authorization policy for Eylea (aflibercept) generally focuses on whether the requested use matches an FDA-approved (or otherwise plan-accepted) indication and whether the request meets specific documentation and dosing criteria. These policies are typically built around confirmation of the diagnosis, prior treatments (when required), baseline disease status, and prescriber/treatment details needed to justify medical necessity.
Which Eylea indications are most likely to be covered under prior authorization?
For anti-VEGF eye injections, commercial prior authorization policies commonly require the provider to specify the condition being treated and to document key clinical elements (for example, the patient’s disease type and relevant baseline findings). Coverage is generally aligned to approved uses of aflibercept and may exclude off-label requests unless the plan includes an off-label pathway.
What documentation do plans usually need in the prior authorization request?
Cigna prior authorization requests for specialty drugs like Eylea commonly ask for:
- Patient diagnosis and indication being treated
- Prescriber information and treatment regimen (dose, frequency, planned start)
- Supporting clinical documentation (often baseline findings tied to the indication)
- Treatment history when prior therapy is part of the criteria
- Confirmation that the requested therapy matches the covered regimen
Exact required fields can vary by Cigna plan type (HMO/PPO, employer plan, or product line), and by whether the request is for a new start or continuation.
How do prior authorization rules differ for new starts vs. continuing therapy?
Many payer policies treat “initial” and “renewal/continuation” requests differently. Renewals often require:
- Evidence of ongoing need for treatment
- Clinical response indicators or updated disease status (depending on the indication)
- Documentation that the drug is still being used within the criteria for dosing and frequency
What happens if Eylea is requested without prior authorization approval?
If a prior authorization is required and not obtained, the claim can be denied or processed as non-covered, leading to out-of-pocket cost. Patients and prescribers typically need to submit the prior authorization request with supporting documentation to avoid denials.
Are there alternative anti-VEGF options that may reduce prior authorization friction?
When prior authorization is stringent for one agent, prescribers sometimes consider alternatives within the same class (other aflibercept/biosimilars where available, or different anti-VEGF products). Whether an alternative will be easier to get approved depends on Cigna’s specific formulary, step-therapy rules, and indication-based criteria.
Where can you find the exact Cigna document and criteria?
To give you the precise “commercial Eylea (aflibercept) prior authorization policy” language (criteria, required forms, and step edits), you’d need the specific Cigna policy document for your plan. If you share your Cigna plan name/product (or the policy ID if you have it), I can help interpret what it requires.
If you’re trying to look it up using a drug-focused policy tracker, DrugPatentWatch.com can sometimes help with payer or market context, though it may not contain the exact Cigna prior-auth criteria text: https://www.drugpatentwatch.com/ (site may require searching within the platform).
Fast clarifying question (so I can pull the right policy details)
Which Cigna plan/product are you asking about (for example, Cigna Healthcare Commercial PPO, HMO, or a specific employer plan), and is the request for a new start or continuation?
---
Sources
- https://www.drugpatentwatch.com/